AMSTERDAM–(BUSINESS WIRE)–Regulatory News:
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical Firm creating innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that its partnership along with The Leukemia & Lymphoma Society (LLS), the world’s largest voluntary good health agency focused on blood cancers, has actually been strengthened along with a second equity investment by LLS in to the progression of Kiadis Pharma’s lead product ATIR101™.
LLS initially invested around US$1 million in February 2016 through an equity investment via its Therapy Acceleration Routine (TAP), a strategic initiative to partner directly along with biotechnology companies to insight accelerate the progression of promising therapies. This second investment will certainly now additionally be used to finance Kiadis Pharma’s second ongoing Phase II trial in leukemia patients which the Firm after that intends to keep on in to a randomized controlled Phase III pivotal study on monitor to begin later this year. The ongoing Phase II trial is investigating the repeated dosing of ATIR101™ as an adjunctive treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) (donor cells from a half-matched related donor) in adult patients along with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). The trial (CR-AIR-008; NCT02500550 / EudraCT 2015-002821-20) is conducted under an IND of the United States Meals and Drug Administration and is established to enroll patients in the United States also as various other countries, including Canada, Belgium, Germany and the United Kingdom.
The second funding by LLS has actually taken place through an equity investment of around US$750,000 and a total of 67,0twenty shares will certainly be issued to LLS.
Manfred Rüdiger, PhD, Chief Executive Officer of Kiadis Pharma, commented: “We are delighted that LLS has actually gained an additional considerable supplement to the progression of our lead product ATIR101™ and invested further in Kiadis Pharma. This is again a durable authorize of self-confidence in just what we do and our objective remains to be to delivering this necessary product to patients when possible.”
Louis J. DeGennaro, Ph.D., LLS’s President and CEO, added: “Kiadis Pharma’s ATIR101™ shows terrific promise in fighting life-threatening infections and graft versus host health problem complying with stem cell transplantations. LLS is pretty pleased to be increasing its degree of support for this Routine which we chance will certainly boost outcomes for patients along with blood cancers.”
About ATIR101™
For patients suffering from blood cancers, an allogeneic hematopoietic stem cell transplantation (HSCT) is generally regarded as the most efficient curative approach. Throughout an HSCT treatment, the bone marrow, harboring the diseased cancer cells, is forever destroyed and subsequently replaced by stem cells in the graft from a healthy and balanced donor. After an HSCT treatment it usually takes the patient at least 6 to twelve months to recover to near-regular blood cell levels and immune cell functions. Throughout this period, the patient is highly vulnerable to infections caused by bacteria, viruses and fungi however additionally to health problem relapse.
ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) provides for a safe donor lymphocyte infusion (DLI) from a partially matched (haploidentical) family member free of the risk of causing serious Graft-versus-Host-health problem (GVHD). The T-cells in ATIR101™ will certainly insight fight infections and remaining tumor cells and thereby bridge the time until the immune system has actually fully re-grown from stem cells in the transplanted graft.
In ATIR101™, T-cells that would certainly trigger GVHD are eliminated from the donor lymphocytes using Kiadis Pharma’s photodepletion technology, minimizing the risk of GVHD and eliminating the necessity for prophylactic immune-suppression. At the exact same time, ATIR101™ contains potential cancer killing T-cells from the donor that could eliminate residual cancer cells and insight avoid relapse of the disease, known as the Graft-versus-Leukemia (GVL) effect.
Therefore, ATIR101™, administered as an adjunctive immuno-therapeutic on top of HSCT, provides the patient along with functional, mature immune cells from a partially matched family donor that can easily fight infections and tumor cells however that do not trigger GVHD. ATIR101™ thus has actually the potential to make curative HSCT a viable option to numerous a lot more patients.
The Firm estimates that around 35% of patients that are eligible and in urgent necessity of HSCT will certainly not discover a matching donor in time. A partially matched (haploidentical) family donor, however, will certainly be available to over 95% of patients.
ATIR101™, consisting of donor T-cells that fight infections and residual tumor cells while not eliciting serious GVHD, is created to result in reasonable relapse rates and reasonable rates of death as a result of infections, in the absence of serious acute GVHD.
About Kiadis Pharma
Kiadis Pharma is focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company’s products have actually the potential to handle the risks and limitations connected along with allogeneic hematopoietic stem cell transplantation (HSCT), namely Graft-versus-Host-health problem (GVHD), cancer relapse, opportunistic infections and limited matched donor availability. The Firm believes that HSCT could become a first-choice treatment for blood cancers, inherited blood disorders and possibly autoimmune diseases and durable organ transplantations.
In April 2016, the Firm reported positive Phase II outcomes along with its lead product ATIR101™ in patients along with blood cancer. The data showed that ATIR101™ significantly reasonable Transplant Related Mortality and significantly improved Overall Survival. In addition, ATIR101™ did not elicit grade III-IV GVHD in any type of patient. ATIR101™ has actually been granted Orphan Drug Designations the two in the US and Europe. The Company’s second product candidate, ATIR201™, addresses inherited blood disorders along with an very first concentrate on thalassemia, a health problem which outcomes in destruction of red blood cells in patients. ATIR201™ is expected to enter Phase I/II clinical progression in the second half of 2016.
Kiadis Pharma, based in Amsterdam, The Netherlands, was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the European Medicines Agency (EMA). The Company’s shares are listed on Euronext Amsterdam and Euronext Brussels. For a lot more write-up visit www.kiadis.com
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections Regarding future events. By their nature, forward-looking statements involve a lot of risks, uncertainties and assumptions that could trigger actual outcomes or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, however not limited to, modifications in demand, competition and technology, can easily trigger actual events, performance or outcomes to differ significantly from any type of anticipated development. Forward looking statements contained in this press release concerning past trends or tasks ought to not be taken as a representation that such trends or tasks will certainly keep on in the future. As a result, Kiadis Pharma expressly disclaims any type of obligation or undertaking to release any type of update or revisions to any type of forward-looking statements in this press release as a result of any type of modification in expectations or any type of modification in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any type of of its subsidiary undertakings or any type of such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any type of responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You ought to not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
